Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)
- Despierre, E.
- Vergote, I.
- Anderson, R.
- Coens, C.
- Katsaros, D.
- Hirsch, F.R.
- Boeckx, B.
- Varella-Garcia, M.
- Ferrero, A.
- Ray-Coquard, I.
- Green, J.A.
- Steer, C.
- Berns, E.M.J.J.
- Casado, A.
- Lambrechts, D.
- Jimeno, A.
ISSN: 1776-260X, 1776-2596
Año de publicación: 2016
Volumen: 11
Número: 3
Páginas: 429
Tipo: Errata